Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature

Kalyani Narra; Hossein Borghaei; Tahseen Al-Saleem; Martin Höglund; Mitchell R Smith

doi:10.1016/j.leukres.2005.05.017

Pure red cell aplasia in B-cell lymphoproliferative disorder treated with rituximab: report of two cases and review of the literature

Leuk Res. 2006 Jan;30(1):109-14. doi: 10.1016/j.leukres.2005.05.017. Epub 2005 Jul 25.

Authors

Kalyani Narra¹, Hossein Borghaei, Tahseen Al-Saleem, Martin Höglund, Mitchell R Smith

Affiliation

¹ Department of Medical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. [email protected]

PMID: 16043218
DOI: 10.1016/j.leukres.2005.05.017

Abstract

Pure red cell aplasia (PRCA) is an unusual cause of anemia in patients with chronic lymphoproliferative disorders. Here, we present two cases of PRCA, one associated with chronic lymphocytic leukemia (CLL) and the other with splenic marginal zone lymphoma, in which the PRCA responded dramatically to treatment with rituximab. We then review the literature on PRCA in lymphoma and response to rituximab. PRCA associated with CLL or lymphoma may be another indication for rituximab therapy.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal / administration & dosage*
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents / administration & dosage*
Female
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / complications
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Lymphoma / complications
Lymphoma / drug therapy*
Lymphoma / pathology
Middle Aged
Red-Cell Aplasia, Pure / complications
Red-Cell Aplasia, Pure / drug therapy*
Red-Cell Aplasia, Pure / pathology
Rituximab

Substances

Antibodies, Monoclonal
Antibodies, Monoclonal, Murine-Derived
Antineoplastic Agents
Rituximab